Denali Therapeutics Inc. (DNLI) has 4 SEC Form 4 insider filings on record in the last 90 days. No insider purchases were filed — 3 sales totalling $370K. Most recent filing: Sept. 9, 2026.
| Date | Insider | Value | Shares | Stake | Pre-planned | Links |
|---|---|---|---|---|---|---|
| Sept. 9, 2026 filed Sept. 4, 2026 | Chin Peter Scott Chief Medical Officer | −$36,868 | 1,654 | −1% | No | |
|
|
||||||
| Sept. 4, 2026 filed Sept. 2, 2026 | Thornberry Nancy Director | −$261,929 | 11,439 | −37% | Yes | |
|
|
||||||
| Aug. 14, 2026 filed Aug. 12, 2026 | Watts Ryan J. President and CEO | $0 | 32,220 | −1% | No | |
|
|
||||||
| Aug. 13, 2026 filed Aug. 11, 2026 | Schuth Alexander O. COFO and Secretary | −$71,625 | 2,857 | −1% | No | |
|
|
||||||
Form 4 is the filing company officers, directors and 10% shareholders must submit to the SEC within two business days of trading their own company's stock. Open-market purchases generally carry more signal than sales, which are often scheduled in advance. More on how this works.
Real-time Telegram alerts the moment a Form 4 is filed. Filings shown here are delayed by 72 hours.
Start free